Custom Search

Rituximab News

Mabthera Approved for Use in Rheumatoid Arthritis in Europe

Unique mode of action brings new treatment option to rheumatoid arthritis suffers with an inadequate response to current biologic therapies.

Rituxan® Effective in Treatment of Splenic Marginal Zone Lymphoma and Marginal Zone Lymphoma

According to the results of a study published in the journal Cancer, the targeted therapy Rituxan® (rituximab) appears to be effective in the treatment of two relatively uncommon types of non-Hodgkin’s lymphoma—splenic marginal...

Rituxan® Effective in Chronic Graft-Versus-Host Disease

According to an early online publication in the journal Blood, the agent Rituxan® (rituximab) appears effective and well tolerated in the treatment of chronic graft-versus-host-disease.

Rituximab Effective in Treating Chronic Graft-Versus-Host Disease

Dana-Farber researchers found that rituximab reduced the severity of chronic graft-versus-host disease (GVHD) in 70 percent of the study participants. Chronic GVHD is a potentially life-threatening complication of donor bone...

Displaying results 21 to 24 out of 24

< Previous






Use of this site is subject to the following terms of use